Cannabinoids reduced a brain appetite signal in sleep-deprived mice, with insulin resistance linked to CB2 receptors

WIN 55,212-2 reduced brain nesfatin-1 immunoreactivity in sleep-deprived mice, an effect prevented by either CB1 or CB2 antagonists. Serum nesfatin-1 levels were unchanged. Insulin resistance was higher in the CB2 antagonist and WIN+CB2 antagonist groups, suggesting CB2 involvement in glucose metabolism.

Sixty mice subjected to 72-hour REM sleep deprivation and treated with WIN 55,212-2 (cannabinoid agonist), AM251 (CB1 antagonist), SR144528 (CB2 antagonist), or combinations. Blood glucose, insulin, and nesfatin-1 measured; brain nesfatin-1 assessed by immunohistochemistry.

This reveals a new connection between cannabinoid receptors and appetite-regulating signals in the brain. The finding that CB2 receptors affect insulin resistance independently adds to evidence that cannabinoids influence metabolism through multiple pathways.

The appetite-stimulating effects of cannabinoids ("the munchies") are well-known but incompletely understood. This study adds nesfatin-1 as another molecular player in cannabinoid appetite regulation, and the insulin resistance finding connects cannabis to metabolic health.

Sleep deprivation model adds a confound. Acute drug administration only. Only male mice. The relationship between central nesfatin-1 reduction and actual eating behavior was not tested.